Scholar Rock Holding SRRK 深 滬
已收盤 06-18 16:00:00 美东时间
47.33
+0.380
+0.81%
華盛通- 最 高48.08
- 今 開47.27
- 成交量 305.93万股
- 最 低 46.165
- 昨 收 46.95
- 總市值 56.71亿
- 52周最高 52.185
- 市盈率 靜 --
- 換手率 2.55%
- 52周最低 27.07
- 委 比 50.00%
- 總股本 1.20亿
- 歷史最高 70.00
- 量 比 3.00
- 振 幅 4.08%
- 歷史最低 4.325
- 每 手 1
- 風險率 6.54%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Scholar Rock shareholders ratify Deloitte as independent auditor
Scholar Rock shareholders ratify Deloitte as independent auditor Scholar Rock held its annual shareholder meeting on June 4, 2026. Shareholders selected four directors for three-year terms running to the 2029 annual meeting. Deloitte & Touche was ratified as independent registered public accounting
06-05 18:02
Scholar Rock将出席杰富瑞全球医疗保健大会，聚焦SMA新药apitegromab关键审批
Scholar Rock公司宣布，管理层将于2026年6月3日上午11：40在纽约出席杰富瑞全球医疗保健大会并进行炉边谈话。此次活动正值公司核心药物api...
05-20 20:55
Scholar Rock Charts High-Stakes Path to SMA Launch
Scholar Rock Holding (($SRRK)) has held its Q1 earnings call. Read on for the m...
05-20 14:52
美股大行评级 | 爱彼迎、Affirm、CoreWeave、Datadog、微芯科技等获多家大行上调目标价；HubSpot惨遭14家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Artiva Biotherapeutics"买入"评级，目标价从15美元升至35美元；韦德布什：维持Cullinan Therapeutics"跑赢大市"评级，目标价从36美元升至37美元
05-11 15:43
Scholar Rock Charts Path to Apitegromab Approval
Scholar Rock Holding (($SRRK)) has held its Q1 earnings call. Read on for the m...
05-09 09:15
HC Wainwright & Co. Maintains Buy on Scholar Rock Holding, Raises Price Target to $65
HC Wainwright & Co. analyst Andres Y. Maldonado maintains Scholar Rock Holding (NASDAQ:SRRK) with a Buy and raises the price target from $58 to $65.
05-08 19:20
Scholar Rock Advances Apitegromab Toward Potential 2026 Launches
Scholar Rock Holding ( ($SRRK) ) has shared an announcement. Scholar Rock on Ma...
05-07 19:58
财报速睇 | Scholar Rock Holding 2026财年Q1营收0.00亿美元，同比增长0.0%；归母净利润亏损1.06亿美元，同比亏损扩大41.2%
华盛资讯5月7日讯，Scholar Rock Holding公布2026财年Q1业绩，公司Q1营收0.00亿美元，同比增长0.0%，归母净利润亏损1.06亿美元，同比亏损扩大41.2%。
05-07 19:48
财报速睇 | Scholar Rock Holding 2026财年Q1营收0.00亿美元，同比增长0.0%；归母净利润亏损1.06亿美元，同比亏损扩大41.2%
华盛资讯5月7日讯，Scholar Rock Holding公布2026财年Q1业绩，公司Q1营收0.00亿美元，同比增长0.0%，归母净利润亏损1.06亿美元，同比亏损扩大41.2%。
05-07 19:34
美股大行评级 | 瑞银大幅上调西部数据、希捷科技目标价！汇丰银行上调英特尔评级至"买入"，目标价从50美元升至95美元
今日重点评级关注：HC Wainwright & Co.：维持Century Therapeutics"买入"评级，目标价从2美元升至5美元；Oppenheimer：维持Climb Bio"跑赢大市"评级，目标价从10美元升至18美元
04-22 12:41
